Inhaled Tobramycin (TOBI®)A Review of its Use in the Management of Pseudomonas aeruginosa Infections in Patients with Cystic Fibrosis

被引:0
作者
Susan M. Cheer
John Waugh
Stuart Noble
机构
[1] Adis International Limited,
来源
Drugs | 2003年 / 63卷
关键词
Cystic Fibrosis; Tobramycin; Colistin; Allergic Bronchopulmonary Aspergillosis; Dornase Alfa;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:2501 / 2520
页数:19
相关论文
共 130 条
[31]  
Dorkin HL(2001)Comparison of inhibitory and bactericidal activity of antipseudomonal antibiotics against Chest 120 107S-41
[32]  
Eisenberg JD(1994) isolates from cystic fibrosis patients J Antimicrob Chemother 34 331-78
[33]  
Stephens D(1987)Development of antibiotic resistance in J Antimicrob Chemother 19 569-7
[34]  
Garey N(1989) during two decades of antipseudomonal treatment at the Danish CF Center Antimicrob Agents Chemother 33 41-45
[35]  
Isles A(1993)Resistance surveillance programs and the incidence of gram-negative bacillary resistance to amikacin from 1967 to 1985 J Clin Invest 91 38-42
[36]  
Weber A(1997)Aminoglycoside resistance: a worldwide perspective Can J Infect Dis 8 335-26
[37]  
Williams-Warren J(2002) activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Chest 122 219-7
[38]  
Ramsey B(2001) isolated from cystic fibrosis patients in southwestern Germany J Pediatr 139 572-9
[39]  
Touw DJ(2003)Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis Am J Respir Crit Care Med 167 841-64
[40]  
Jacobs FAH(2002)Administration of aerosolized antibiotics in cystic fibrosis patients Eur Respir J 20 658-51